The Evoque transcatheter tricuspid valve replacement (TTVR) system continued to show significant benefits 1 year after implant, according to an update from the TRISCEND II trial. Among study ...

The overall evidence for the procedure is “insufficient” at present, but good enough to allow coverage, the agency says.

Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed ... Images in Clinical Medicine ... 4,24–26; studies show that patients who received a permanent ...

Transcatheter tricuspid repair reduced valve regurgitation and improved quality of life at 1 year even for the sickest patients, but mortality remained high, new analysis of TRILUMINATE trial shows.

In the midst of transformative transcatheter approaches to repair diseased aortic and mitral valves, the tricuspid valve has been overshadowed, according to Michael E. Bowdish, MD, vice chair of ...

If a person’s heart valves become damaged, they may benefit from having heart valve replacement surgery. Doctors may assess a person's suitability for the surgery. Learn more here.

CMS has approved Medicare and Medicaid coverage for transcatheter tricuspid valve replacement procedures for the treatment of symptomatic tricuspid regurgitation.. The procedures will be subject ...

A team at HonorHealth Scottsdale (Ariz.) Shea Medical Center performed the state’s first tricuspid valve replacement using the Edwards Lifesciences’ Evoque system outside of a clinical trial.

Laplace Interventional, a US-based medical device company focusing on transcatheter valve technology, recently announced the successful completion of a Series C funding round worth $22 million.

Joan Mertz, 83, became the first patient in the state to undergo an artificial heart valve replacement without the need for open-heart surgery. Latest U.S.

Source Reference: Hahn RT, et al "Transcatheter valve replacement in severe tricuspid regurgitation" N Engl J Med 2024; DOI: 10.1056/NEJMoa2401918. Share on Facebook. Opens in a new tab or window ...